Industry Satellite Symposia
CONSENSUS OR CONTROVERSY? - Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Patients with Locally Advanced Non-Small Cell Lung Cancer
Sunday, September 15
6:00 PM - 8:00 PM
Location: Hyatt Regency McCormick Place, Regency Ballroom CDE
6:00 p.m. – 6:30 p.m. Registration
6:30 p.m. – 8:00 p.m. Symposium
Hyatt Regency McCormick Place, Regency Ballroom CDE
Dinner will be provided.
Accreditation: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Credits: Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience: This activity is intended for radiation oncologists, medical oncologists, fellows in these fields, and other healthcare professionals involved in the management of patients with lung cancer.
- Consult pathologic assessments, imaging and other paraclinical tools to accurately state patients with newly diagnosed Stage III non-small cell lung cancer (NSCLC) and utilize this information to design an appropriate treatment plan for these individuals.
- Appreciate the benefits, risk, and long-term outcomes associated with the use of local and/or systemic treatment modalities in the management of patients with resectable locally advanced NSCLC, and consider this information when counseling individuals regarding current therapeutic recommendations.
- Analyze the biologic basis for investigation of immune checkpoint inhibitors in patients with non-metastatic NSCLC.
- Appraise the FDA approval of anti-PD-L1 antibody consolidation for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
- Recognize immune-related adverse events and other common side effects associated with the use of consolidation anti-PD-L1 antibody therapy for patients with Stage III NSCLC, and offer supportive strategies to minimize and/or manage these toxicities.
- Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized or locally advanced NSCLC, and counsel appropriate patients about availability and participation
To register or for more information, please visit http://www.researchtopractice.com/Meetings/Chicago/NSCLC2019
This activity is supported by an educational grant from AstraZeneca